HOOKIPA Pharma Inc.

HOOKIPA Pharma Inc. develops arenavirus-based immunotherapeutics designed to induce robust antigen-specific CD8+ T cell and antibody responses for treatment of cancer and infectious diseases. Its main product candidates include replicating and non-replicating arenaviral therapies such as HB-700 (KRAS-mutated cancers), eseba-vec/HB-200 (HPV16+ cancers), HB-300 (prostate cancer, development paused) and Gilead-partnered HB-400 (HBV) and HB-500 (HIV). The company operates through two primary segments: immuno-oncology programs and infectious disease collaborations/licensing. It advances programs via clinical trials and strategic partnerships, using contract manufacturers and global clinical sites in the U.S., Europe and other regions.

Summary from filing dated 2025-02-28